- View All Journals
- Expert Opinion on
- Expert Review of
- Anticancer Therapy
- Anti-infective Therapy
- Cardiovascular Therapy
- Clinical Immunology
- Clinical Pharmacology
- Endocrinology & Metabolism
- Gastroenterology & Hepatology
- Medical Devices
- Molecular Diagnostics
- Obstetrics & Gynecology
- Pharmacoeconomics & Outcomes Research
- Respiratory Medicine
- Current Medical Research and Opinion
- Journal of Medical Economics
- Journal of Drug Assessment
- View All Books
- View Book Series
- Basic and Clinical Dermatology
- BioMed Tracker Reports
- Clinical and Basic Science Dermatology
- Cosmetic Science and Technology
- Drugs and the Pharmaceutical Sciences
- European Society of Medical Oncology
- Fundamental and Clinical Cardiology
- Infectious Disease and Therapy
- Lung Biology in Health and Disease
- Medical Psychiatry
- Reproductive Medicine/Assisted Tech
- Series in Cosmetic and Laser Therapy
- Series in Dermatological Treatment
- Series in Maternal-fetal Medicine
- Target Organ Toxicology
- Translational Medicine
- Encyclopedias and Reference Works
- Expert Opinion on Cardiovascular Disease
- Expert Opinion on Haematology
- Expert Opinion on Infection
- Expert Opinion on Musculoskeletal Disorders
- Expert Opinion on Neurology
- Expert Opinion on Oncology
- Expert Opinion on Psychiatry
- Expert Opinion on Respiratory Disease
- Informa Healthcare Diabetes Collection
Expert Opinion on Pharmacotherapy
About the Journal
- Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives
Dennis A Eichenauer,
- Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium)
Parth J Parekh,
Edward C Oldfield,
David A Johnson
- Pharmacotherapy for restless legs syndrome
- Protein kinase inhibitors to treat non-small-cell lung cancer
- Lipid pharmacotherapy for treatment of atherosclerosis
Stephen J Nicholls,
Anthony D Pisaniello,
April 17, 0014This month Expert Opinion have delved into the various treatments available for melanoma
April 9, 2022
Look no further than these (some FREE) articles from Expert Opinion’s April issues!
April 1, 2022Dimitri Mikhailidis Editor in Chief of Expert Opinion on Pharmacoherapy chooses Drug Evaluation on the recently approved Alogliptin benzoate for the treatment of type 2 diabetes as the Editors pick from the first half of our April content!
March 7, 2022Expert Opinion on Pharmacotherapy has recently published a review and an editorial trying to answer this question.
February 21, 2022New topical treatments for psoriasis by Chiricozzi et al. is our pick of the Expert Opinion on Pharmacotherapy March issue from Editor-in-Chief Dimitri Mikhailidis (UCL, London). Read more here
February 21, 2022This month in Expert Opinion, treatments for pulmonary arterial hypertension are considered. We cover drugs that are established, recently approved and in phase III trials as well as evaluating the management of the condition in patients with congenital heart disease.
February 17, 2022First-in-Class drugs and their novel mechanisms of action are the focus of the first Expert Opinion and Expert ReviewsCross-series themed issue. All articles will be published in their respective journals between January and April 2022 so half of them are already available!
January 27, 2022Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has chosen the drug evaluation: Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention by Skala et al., as the Editor’s pick for the February issues.
December 18, 2013The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!
December 17, 2013Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has chosen this exciting topic on: Chemotherapeutic inhibitors in the treatment of prostate cancer by Dou QP et al, as the pick of the month for the January 2022 issue.
December 13, 2013
Five articles from the Expert Opinion Series are within the top 100 most accessed articles from the Informa healthcare journal portfolio in November 2013
November 29, 2013Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has picked the review article: An update on the pharmacotherapy for endometrial cancer by Scambia et al, as the highlight of the month for the December issues.
November 5, 2013All reviews in the November issue focus on oncology – check them out here..
October 22, 2013This Week in the Expert Opinion journals, we look into new and not-so-new therapies for cancer, the pharmacokinetics of a common contraceptive, and wonder what special considerations are needed for clinical trials of orphan drugs. Find out more here…
October 15, 2013Editor-in-Chief, Professor Dimitri Mikhailidis (Royal Free Hospital, UK), has picked the original research: Effects of canrenone in patients with metabolic syndrome by Derosa et al, as the November issue’s editorial highlight.
October 1, 2013This month the Editor highlights the drug evaluation article on pimavanserin: a novel agent, for a novel indication with a novel mechanism of action!
August 28, 2013Introducing omacetaxine mepesuccinate. This semisynthetic formulation of a natural alkaloid with a novel mechanism of action, was granted accelerated approval by the FDA in October 2012, for subcutaneous use in adult CML patients, who are resistant to at least two tyrosine kinase inhibitors.
August 20, 2013This month’s Editor’s pick focuses on the very interesting topic regarding the use of antiretroviral agents in pre-exposure prophylaxis, and how this novel biomedical intervention can prevent the transmission of HIV among high-risk populations.
August 16, 2013The FDA defines a First-in-Class drug as one which uses a new and unique mechanism of action for treating a medical condition. This is a concept that immediately makes you think of words like ‘innovation’, ‘novelty’, ‘potential’, ‘pioneering’ and ‘cutting-edge’ – all things that most pharmaceutical companies look for when considering areas of R&D to pursue and invest in. While they have the potential to boost the company’s pipeline and its profit, First-in-Class drugs also come with much greater risk and are definitely not guaranteed to succeed.
July 18, 2013August’s pick of the month focuses on the most powerful triptan available for acute migraine: sumatriptan.
June 24, 2013
European patent for Pfizer’s Viagra expires – 21st June 2013
Despite extending the patent protection on Viagra (sildenafil) in the US until 2020, Pfizer now has to face the effects of patent expiration in the UK and other countries in Europe.
June 13, 2013July’s pick of the month is a very interesting drug evaluation paper written by Ballantyne and colleagues, on the role of icosapent ethyl for the treatment of hypertriglyceridemia.
May 30, 2013June’s pick of the month is an excellent drug evaluation paper by Aggarwal and Showkathali, who evaluate the pharmacology, efficacy and safety of rosuvastatin, as well as statin use in acute coronary syndromes.
May 22, 2013Expert Opinion on Investigational Drugs would like to present a special issue dedicated to protein kinase inhibitors. These small molecules have potential to be active therapies in a wide variety of indications, from oncology through to neurology and beyond. Along with Guest Editor Tomi Sawyer, we explore some of the interesting drugs which fall into this class in this special issue of EOID.
April 24, 2013This month’s pick by the Editor is the pharmacotherapy options for cataplexy, one of the major symptoms of the sleeping disorder narcolepsy.
March 14, 2013
In this month’s issue, Fabi and colleagues explore whether Epidermal Growth Factor Receptor (EGFR) gene copy number has any significance on lapatinib sensitivity, in HER2-positive metastatic breast cancer.
(This article is currently early online, but will be published in April Vol 14 issue 6)
October 24, 2012Showing once again how relevant and interesting the reviews in the Expert Opinion series are, ipilimumab, winner of the best biotechnology product and telaprevir, joint winnder of best pharmaceutical agent, have recently been the subject of review articles.
August 29, 2012This month, scientists from two of the world’s leading institutions, Harvard Medical School and Cambridge University, compare three newer atypical antipsychotic drugs, in an article published in Expert Opinion on Pharmacotherapy.
July 13, 2012This month’s issue of Expert Opinion on Pharmacotherapy (EOP) is a special themed issue, dedicated to atypical antipsychotics!
June 25, 2012What is known about QT prolongation and analgesic drugs? Professor Robert Raffa and co-authors address this important question in the current issue of Expert Opinion on Pharmacotherapy.
June 22, 2012Hair loss is a common complaint. In this month’s issue, Dr Tosti and Dr Miteva form the University of Miami Miller School of Medicine review current and future treatment options for alopecia.
They update the literature since the release of the first edition of this article 3 years ago. They conclude that significant research success has been achieved through the discovery of the genetic profile of alopecia areata and the PPAR-γ pathway in scarring alopecia.
March 27, 2012In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.
March 26, 2012In our April issue, Dr Manzouri and colleagues from Moorfields Eye Hospital outline the corneal transplant procedure and the treatment options available in the management of transplant rejection.
March 2, 2012This month, Professor Guido Grassi has written an interesting evaluation of the TALENT study for Expert Opinion on Pharmacotherapy.
February 22, 2012
This weeks DocGuide has included a popular Treatment Evaluation, which was published in the February issue of EOP!
In this evaluation, Dr Teramoto, from the Teikyo University School of Medicine, discusses the clinical impact of Pitavastatin in comparison to other statins on LDL-C and HDL-C.
Click here to read how Pitavastatin performed in i) Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL): the PATROL Trial; ii) various Phase III clinical trials in Western countries; iii) The Comparison of Preventive Effect on Cardiovascular Events With Different Statins (CIRCLE) study; and iv) The Livalo Effectiveness and Safety (LIVES) Study Extension.
February 9, 2012In this months issue, the editor would like to highlight an evaluation of sorafenib for the treatment of renal cancer.
February 1, 2012
One of EOP’s recently published Drug Evaluations, “Paroxetine for the treatment of depression”, has been included in DocGuide’s most popular articles!
Drs Gibiino and Serretti from the Institue of Psychiatry at the University of Bologna, evaluate the latest data on paroxetine and investigate its clinical efficacy and safety in different groups of patients.
Click here to read this Drug Evaluation
January 17, 2012This months highlighted article provides a comprehensive guide for the use of Tapentadol for the treatment pain, by Dr Hartrick.
January 16, 2012Our Editor’s pick this month discusses antiplatelet therapy in acute coronary syndromes, by Dr Menozzi and colleagues.
November 16, 2011Informa Healthcare’s recently launched CMEcast service announced today that its first four educational courses have received official approval from the European Board for Accreditation in Cardiology (EBAC) as EBAC Accredited Educational Programmes.
Targeted Media, Inc. a Time Inc. company, expands partnership with Informa Healthcare CommunicationsAugust 31, 2011
August 31, 2011 – New York, NY – Targeted Media, Inc., a Time Inc. company, has named Informa Healthcare Communications as their exclusive sales agent for ‘The Educated Patient’ series and pharma-sponsored magazine subscriptions in Europe. This builds upon their existing partnership in the US, where Informa Healthcare Communications provides content and creative direction for the series. Informa Healthcare Communications, a division of the global STM publisher Informa Healthcare, produces medical content tailored to both physicians and patients.